SynthesisClinical rheumatology2025
Risk factors in systemic lupus erythematosus-associated Sjögren's syndrome: multicenter case-control studies and systematic review.
Synthesis in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study identifies risk factors for SLE-associated Sjögren's syndrome (SLE-SS), based on multiple cohorts and meta-analysis.
methodsThree cohorts (Luzhou cohort, Enshi cohort, and Chengdu cohort) were initially conducted, and clinical, laboratory characteristics from patients with SLE-only and SLE-SS patients were collected and we discussed risk factors related to SLE-SS. Subsequently, a meta-analysis discussed risk factors related to SLE-SS risk from published articles and our studies.
resultsFor original cohort studies, 1904 SLE patients were included in the Luzhou cohort, and there were 36 SLE-SS patients. Results showed that factors such as age (OR = 1.07), anti-SSB ( +) (OR = 3.68), and anti-RNP ( +) (OR = 3.42) were risk factors for SLE-SS risk. In the Enshi cohort, 386 SLE patients were included, and there were 18 SLE-SS patients. Results showed that factors such as age (OR = 1.10), ANA ( +) (OR = 0.08), and RF ( +) (OR = 20.09) were positively related to SLE-SS risk. For the Chengdu cohort, 658 SLE patients were recruited, and 88 were SLE-SS patients. Factors such as age (OR = 1.03), ANA ( +) (OR = 0.40), anti-SSA ( +) (OR = 6.23), and anti-SSB ( +) (OR = 3.03) were risk factors for SLE-SS development. In the meta-analysis, 15 original studies were discussed. The meta-analysis identified several risk factors for SLE-SS, including age, anti-SSA ( +), anti-SSB ( +), RF ( +), Raynaud's phenomenon ( +), hematuria ( +) and pulmonary involvement ( +).
conclusionAge, autoantibodies (including anti-SSA, anti-SSB, and anti-RNP), RF, and clinical features (including Raynaud's phenomenon, hematuria, and pulmonary involvement) serve as risk factors for SLE-SS patients. Key Points • Age is a demographic risk factor for SLE-SS; clinical and laboratory characteristics like Raynaud's phenomenon, hematuria, anti-SSA (+) are SLE-SS risk factors. • Meta-analysis showed that characteristics like pulmonary involvement (+), anti-SSB (+), and RF (+) as additional risk factors distinguished SLE-SS patients.
Indexed as
Identifiers
40866767What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.